| SYDNEY, Australia – 20 May 2019 – The Board of Imugene Limited today announced the appointment of leading biotechnology executive and entrepreneur Dr Jens Eckstein as a Non-Executive Director, effective 20 May 2019. Dr. Eckstein recently joined Apollo Ventures as Managing Partner. Before that Dr. Eckstein was President of SR One Ltd., the corporate venture capital arm of GlaxoSmithKline which invests globally in emerging life science companies pursuing innovative science with significant impact on medical care and patients. Imugene Executive Chairman, Paul Hopper said: “Imugene continues to attract a world class team. We welcome Dr Eckstein to the Board and look forward to working together to advance our highly promising cancer immuno therapy pipeline.” Dr Eckstein currently serves on the boards of several biotechnology companies. He was co-founder and Director at Palleon Pharmaceuticals, and co-founder and Director at Decibel Therapeutics. He has served as a Director at ZappRx, Director at Gladius Pharmaceuticals, Chairman and Director at Thrasos Therapeutics, and Director at Alios Biopharma (acquired by Johnson & Johnson). Dr Eckstein has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies. He is a Kaufman Fellow, founder of Action Potential Venture Capital (APVC) and created OneStart, the world’s largest life science accelerator. He was a General Partner at the trans-Atlantic venture capital firm TVM Capital. Dr Eckstein holds several issued patents and has authored a number of scientific publications. He earned his Doctorate, summa cum laude, in Biological Chemistry in at the University of Konstanz and Harvard University. Subject to shareholder approval, the Company agrees to issue 25 million unlisted options exercisable at A$0.04 (5 mil options), A$0.042 (10 mil options) and A$0.045 (10 mil options) per option expiring 3 years from the date of approval to be vested over 24 months to Dr. Jens Eckstein. | 
